Share Skyrockets on news of positive early-stage results from GEN-009 Clinical Trials
Genocea Biosciences, Inc. (NASDAQ: GNCA) skyrocketed today based on news of promising data from its early stage clinical trials of GEN-009, its neoantigen vaccine candidate. There has been a stream of positive news from the company’s stables off late, including news of Journal of Clinical Oncology® selecting...
